Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00127530 · ClinicalTrials.gov registry record · Phase 3
Study of Oral Fampridine-SR in Multiple Sclerosis
A Phase 3 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00127530 is a Phase 3 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 300 participants.
The verdict
NCT00127530, a Phase 3 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
To assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) Fampridine-SR in patients diagnosed with multiple sclerosis (MS), in a double-blind, placebo-controlled, parallel group study.
Interventions
- DRUG Placebo
- DRUG Fampridine-SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00127530
The ClinicalTrials.gov registry entry for NCT00127530 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00127530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00127530 about?
NCT00127530 is a clinical study titled "Study of Oral Fampridine-SR in Multiple Sclerosis". To assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) Fampridine-SR in patients diagnosed with multiple sclerosis (MS), in a double-blind, placebo-controlled, parallel group study.
What is the current status of trial NCT00127530?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2005-05. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00127530?
The interventions under investigation include: Placebo (DRUG), Fampridine-SR (DRUG).
Who is sponsoring clinical trial NCT00127530?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.